Life Sciences Archive » December, 2012

Life Sciences - December, 2012

154 articles

• Judge Unseals FCA Suit Against Millennium, Schering
• NECC Buckles Under Meningitis Suits, Files For Ch. 11
• Push For More Animal Antibiotics Data Could Expose Secrets
• Former SAC Manager Won't 'Flip' In Insider Trading Case
• Vaccine Buyers Get Sanofi's Antitrust Claim Scrapped
• Gilead Ditches Double-Patenting Claim In Tamiflu Suit
• RI Judge Finds Aredia Suit Against Novartis Time-Barred
• Pfizer To Pay $1M Over Ore.'s Claims It Flouted Ads Pact
• Allergan Rivals' Eyelash Treatments Are Drugs, Court Rules
• The Year The AIA's Post-Grant Processes Took Hold
• EU AstraZeneca Ruling — A Letdown For Life Sciences Cos.
• DOJ Drops $83M FCA Medicare Case Against Fresenius
• Ex-Banker Nabbed Over Role In $2B Olympus Accounting Scam
• Indiana Won't Sign Onto $48M Healthpoint FCA Deal
• GSK Tells 3rd Circ. Thalidomide Row Belongs In Fed. Court
• Judge Questions Validity Of Cephalon's Epilepsy Drug Patent
• Half Of Venable's Requested Fees Granted In FTC Acai Suit
• Eli Lilly Strikes $29.4M Settlement Over FCPA Claims
• Ky. AG Can't Escape Merck Outside Counsel Case
• Wilson Sonsini Expands China Practice With Beijing Office
• FDA Slaps New Warning On Vertex's Hep C Drug After Deaths
• Beware Discovery In 3rd-Party Litigation Funding
• GSK To Pay $150M To Settle Direct Purchasers' Flonase Suit
• States Push FDA To Hone Compounding Oversight Plan
• Sanofi Pays $109M For Fine Dining Kickbacks, Illicit Samples
• Bard Defends Fed. Circ. Ruling In Graft IP Case To High Court
• DC Circ. Shelves Contraception Suit To Await ACA Rule
• Bard Survives Bid To Remand Vascular Filter Defect Suit
• Battle Over Labeling Genetically Modified Food Continues
• Ex-S&N Reps Barred From Client Contact In $56M Secrets Row
• Pa. Hospital Hits Cardinal, Owens & Minor With Antitrust Suit
• FDA Signals Fresh Scrutiny Of Opioid Painkillers
• Plan To Share Clinical Data Could Stifle EU Drug Innovation
• IRS Lends Device Makers Leeway On Industry-Loathed Tax
• Seller Of Fake Diabetic Test Strips Gets 5 Years Probation
• FDA Says 5 Eye Care Providers' Lasik Ads Mask Risks
• Ex-Takeda Contractor Loses Bid To Revive 2 FCA Suits
• Amgen Cops To Aranesp Misbranding, Will Pay $762M
• Stryker, Others Face FCA Suit Over Pain-Pump Marketing
• Drug Co. Lied About $245M Buyout Offer, SEC Claims
• Emerging Trends In Nucleic Acids And Human Genome Work
• SG Urges Justices To Reject Hatch-Waxman Safe Harbor Case
• FDA Issues New Guidelines On Clinical Trial Enrichment
• Novartis Gets Expert Testimony Blocked In Aredia-Zometa MDL
• Bayer One-A-Day False Ad Class Action Axed
• Lab Testing Co. Genelex Hit With DNA Patent Suit
• Drug Supplier Possibly Lied About FDA Docs, Judge Says
• 'Don't Ask, Don't Waive' Standstills And The Auction Problem
• More Flexibility On Gift-Giving For Pharma Manufacturers
• Aalto's Faulty-Vial Suit Belongs In Fed. Court, Wheaton Says
• Drug Co. Misrepresented Products' FDA Status, SEC Says
• Orthofix To Pay $42M To End DOJ Medicare Fraud Case
• Genzyme, Cobrek End Kidney Drug Patent Fight
• Fed. Circ. Upholds AstraZeneca's Crestor Patent
• Mylan's Latest Focalin ANDA Brings Novartis IP Suit
• Diversion Scheme Faked Origin Of $440M In Drugs, US Says
• Caronia And The 'New' 1st Amendment Safe Harbor
• FCPA Guide's Lessons For Life Sciences Companies
• Pfizer Loses Bid To Undo Retaliation Verdict In 2nd Circ.
• US Targets Vein Treatment's Marketing In FCA Suit
• Merck Must Hand Over Vioxx Gov't Docs, NJ Judge Says
• Vertical Pharma Suit Claims Deloitte Derailed Acquisition
• Lathrop & Gage Boosts IP Practice With Boutique
• FDA Directs Drugmakers To Make Drugs Less Confusing
• Astellas Seeks To Block Fresenius Generic Adenoscan
• J&J Balks At Ark.'s $181M Risperdal Legal Fee Request
• Why The FCC Matters To Medical Devices
• EU Unitary Patent System Has Major Cos. Wary
• Endo Targets Actavis Over Generic Versions Of Opana
• Plaintiffs Drop Accutane Suits Booted From Philly Tort System
• Pfizer Chantix Trials Show More Heart Troubles In Users: FDA
• Boston Scientific Says 1st-To-File Rule Bars Kickback Suit
• Pfizer Reaches $42.9M Accord With States In Marketing Row
• Roche Says NJ Judge Biased In Accutane Mass Tort Litigation
• Novartis' Exelon Patent Is Invalid, UK Appeals Court Says
• Gilead Shells Out $510M For YM BioSciences
• Allergan Can't Dodge Trade Secrets Suit, NJ Judge Rules
• Pfizer Pays $55M For Off-Label Promotion Of Wyeth's Protonix
• How Justices May Be Leaning In Amgen Argument
• Noteworthy Lessons From FDA Suspension Of Sunland
• Lilly Sues USPTO For Extra 1.5 Years On Cancer Patent
• Philips Can't Escape Consumer Class Action Over AirFloss
• GSK Asks Supreme Court To Weigh Double Avandia Damages
• SEC Can't Prove Stock Buyback Scheme, GSK Unit Says
• Stryker, Wright Medical Settle Suit Over Knee Implant Website
• Meningitis Plaintiff Seeks To Bar NECC From Shredding Docs
• US Must Give Medicare Info In $726M Heart Implant FCA Suit
• New FDA Guidance: What Review Boards Should Do
• Patent Validity Issue Underpins High Court Pay-For-Delay Case
• Zimmer Loses Bid To Pare Suit From Knee Implant MDL
• Sullivan & Cromwell Guides Amgen on $415M DeCODE Buy
• Generics Cos. Ask Fed. Circ. To Nix Pfizer's Lyrica Patent
• Senators Want $29B Medical Device Excise Tax Put On Hold
• 2nd Circ. Backs Another Eli Lilly Win In Zyprexa MDL
• Weston Presidio Sells Evenflo Breastfeeding Unit To PE Firm
• Del. Court Asks France To Compel Bristol-Myers VP's Testimony
• Mass. Pharmacies Now Under Greater Scrutiny
• Mylan Claims Ranbaxy Sitting On Hypertension Drug Exclusivity
• Calif.'s Prop 37 And Food Policy: What Happens Next?
• Medline Workers Ask 9th Circ. For Class Cert. In Wage Case
• Pfizer, Genentech Target Roxane Over Generic Cancer Drug
• Supreme Court To Hear FTC Pay-For-Delay Antitrust Suit
• Lawmakers Want Compounding Group To Cough Up Docs
• Kilpatrick Adds Life Sciences Patent Ace In Atlanta
• No Immediate Appeal For Ex-ArthroCare Execs In SEC Suit
• RI Health Workers Sue To Block State's Flu Shot Mandate
• Zimmer Loses Bid For $1.4M Award In Stryker Poaching Suit
• Pharma Groups Take On Calif. County's Drug Disposal Rule
• Carlyle's Claris Sells $194M Stake, Forms Injections JV
• EU AstraZeneca Ruling Raises Bar For IP Monopoly Abuse
• Free Speech Protects Unapproved Drug Marketing, 9th Circ. Told
• Meningitis Plaintiffs Likely To Get Peek At NECC Facility
• K-Dur Doesn't Apply To Authorized Generic Deals, Judge Says
• 39 Nexium Bone Density Suits Consolidated By MDL Panel
• House Dem Pushes For Health IT Funding, New FDA Office
• House Dems Float Compounding Oversight Bill
• McKesson Pays $9.84M To Settle Ky. Drug Price Inflation Suit
• Drug Labs Alkem, Sidmak Sued Over Acne Drug ANDA
• Cardinal, Owens & Minor Hit With $200M Antitrust Suit
• Recent Life Sciences Patent Cases: Sound The Alarm?
• Healthpoint, DFB To Pay $48M To End FCA Drug Suit
• Life Sciences MVP: Weil's Liz Weiswasser
• Landmark 2nd Circ. Decision Means Victory For Pharm Cos.
• K-V Pharma, Hologic Eye $60M Deal To End Makena Feud
• Clinics Can't Dodge Varian Cancer Device Patent Claims
• IRS Finalizes $29B Medical Device Excise Tax
• OPM Details Multistate Health Plans On ACA Exchanges
• Life Sciences MVP: Morgan Lewis' Randall Sunberg
• FDA Wrongfully Withheld Animal Antibiotic Data, Suit Says
• Walgreen Demands Toss Of Suit Over Joint Products Labeling
• J&J Exits Ex-Sales Reps' Suit Over Noncompete Deal
• Bayer Blasts Expert In Vitamin False Ad Class Action
• 2nd Circ. Ruling Presents Risks For Drug Cos. In Litigation
• Align Technology Execs Netted $52M Via Fraud, Suit Says
• Importers Didn't Breach Kaneka's Enzyme Patent, ITC Finds
• Pfizer Tells 8th Circ. Generic Drug Injury Claims Fail
• Travelers, St. Paul Fight Coverage of W.Va. 'Pill Mill' Suit
• Life Sciences MVP: O'Melveny's Paul Scrivano
• Dorsey & Whitney Draws Medical Device Pro To Calif. IP Team
• Kirkland & Ellis Aids Linden's $314M Dental Co. Buyout
• Ranbaxy Hit With Class Action Over Generic Lipitor Recall
• A Troubling Trend For Personalized Medicine Patents
• Kirkland Guides Baxter's $4B Buy Of Dialysis Co. Gambro
• 1st Circ. Set To Weigh In On FCA First-To-File Rule
• P&G, Canfield Sue Over Skin Imaging Patents
• Myriad Patent Case Tees Up 2 Key Issues For High Court
• Heart Docs Hit Forest Labs With Class Action Over Junk Faxes
• Life Sciences MVP: Kirkland & Ellis' Jay Lefkowitz
• 2nd Circ. Shields Drugmakers From Gov't Marketing Probes
• Nonprofit Fights Sanofi Subpoena In Antitrust Suit
• Plaintiffs Lose Doc Request In Pfizer Epilepsy Drug MDL
• GCs Name Most Arrogant Law Firms
• Endo Claims Opana Generic Versions Ripe For Misuse, Abuse
• Supreme Court Won't Examine Fen-Phen Atty's Fraud Conviction